Courtney Andersen studies the role of estrogen receptor-alpha in ovarian cancer.
Chris Barnes investigates the structural details by which transcription factor activity regulates RNA Polymerase II during the universal process of eukaryotic gene expression.
Soma Jobaggy studies nitrated fatty acid pharmacology and the antioxidant response in hypertensive end-organ damage.
Allison Nagle studies growth factor receptor signaling in breast cancer.
Lin Zhang, PhD
2.42a Hillman Cancer Center
Pittsburgh, PA 15232

Phone: 412-623-1009

Fax: 412-623-7778


BS (Biochemistry), Sichuan University, Chengdu, P.R. China, 1990

PhD (Molecular Biology), University of Southern California, 1995

Postdoctoral Fellow, Johns Hopkins Oncology Center, 1995-1999

Research Areas
Cancer Pharmacology
Signal Transduction
Drug Discovery
Photo of Lin Zhang, PhD

The immediate goal of our research is to understand how anticancer drugs kill cancer cells, and more importantly, why they fail so often.  In the long term, we will attempt to use this knowledge to identify novel molecular targets and treatment strategies to improve cancer chemotherapy and chemoprevention.

Cell death in anticancer therapies

Our research program has centered on several molecules that control discrete steps of programmed cell death. The first one, PUMA, is a downstream target of the tumor suppressor p53 and a BH3-only Bcl-2 family protein.  PUMA is required for DNA damage-induced and p53-dependent apoptosis, and also plays a key role in apoptosis induced by several targeted anticancer drugs.  The second one, SMAC, is a mitochondrial apoptogenic protein and a caspase activator.  SMAC helps to execute apoptosis induced by anticancer drugs via a mitochondrial feedback loop.  Regulators of non-apoptotic cell death, such as the autophagy inducer Beclin 1 and the necrosis regulator RIPK3, have also been studied.  Through analyses of these molecules and their associated protein networks, we try to gain deep understanding on how cell death is initiated and executed in human cancer cells, why some cancer cells are not sensitive to anticancer drugs, and what can be done to restore their sensitivity.

Oncogenic stem cells as the target of cancer chemoprevention

Prevention of human cancer through the use of chemical agents such as non-steroidal anti-inflammatory drugs (NSAIDs) has emerged as a promising strategy to reduce morbidity and mortality of cancer.  Our recent studies showed that intestinal stem cells that have acquired oncogenic alterations are targeted by NSAIDs in chemoprevention of colon cancer.  We are investigating how NSAIDs trigger apoptosis in such oncogenic stem cells, and if induction of apoptosis is critical for the chemopreventive effects of NSAIDs.  We will also determine if apoptosis regulators can be used as markers to predict outcomes of chemoprevention of cancer patients, and if manipulation of apoptosis regulators can be used to improve the chemopreventive effects of NSAIDs.

Manipulation of cell death regulators

To target PUMA, we have developed a high-throughput screening system for identifying small molecules that can activate PUMA in p53-deficient cancer cells.  In collaboration with the Pittsburgh Drug Discovery Institute, we will screen compound libraries to identify novel PUMA inducers.  We have also identified and characterized small molecules that mimic the functional domains of PUMA and SMAC.  Efforts are undertaken to apply these small molecules to chemotherapy and chemoprevention.

Important Publications
Tong J, P Wang, S Tan, D Chen, Z Nikolovska-Coleska, F Zou, J Yu and L Zhang. Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Research 77: 2512-2521, 2017.
Chen D, J Yu and L Zhang. Necroptosis: an alternative cell death program defending against cancer. BBA Reviews on Cancer. 1865:228-236, 2016.
Tong J, S Tan, F Zou, J Yu and L Zhang. FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation. Oncogene; 36:787-796, 2016.
Leibowitz B, W Qiu , ME Buchanan, F Zou, PV Vernon, MP Moyer, XM Yin, RE Schoen, J Yu and L Zhang. BID mediate selective killing of APC-deficient cells in intestinal tumor suppression by non-steroidal anti-inflammatory drugs. Proc. Natl. Acad. Sci. USA.  111:16520-16525, 2014
Chen D, L Wei, J Yu and L Zhang. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clinical Cancer Research 20: 3472-3484, 2014
Peng R, JS Tong, H Li, B Yue, F Zou, J Yu and L Zhang.  Targeting Bax interaction sites reveals that only homo-oligomerization sites are essential for its activation. Cell Death & Differentiation. 20: 744–754, 2013
Li H, P Wang, Q Sun, WX Ding, XM Yin, RW Sobol, DB Stolz, J Yu and L Zhang. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase-8 mediated cleavage of Beclin 1. Cancer Research 71:3625-3634, 2011.
Qiu W, B Wu, X Wang, M Buchanan, MD Regueiro, D Hartman, RE Schoen, J Yu and L Zhang. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in humans and mice. Journal of Clinical Investigation. 121:1722-1732, 2011.
Qiu W, X Wang, B Leibowitz, H Liu, N Barker, H Okada, N Oue, W Yasui, H Clevers, RE Schoen, J Yu and L Zhang. Chemoprevention by nonsteroidal anti-inflammatory drugs eliminates oncogenic intestinal stem cells via SMAC-dependent apoptosis. Proc Natl Acad Sci USA 107:20027-20032, 2010.


12/13/2018 10:45 AM Molecular Pharmacology Journal Club
Song-My Hoang

12/13/2018 12:00 PM Pharmacology & Chemical Biology Seminar Series
Chris Bakkenist, Ph.D.

12/17/2018 12:00 PM Pharmacology & Chemical Biology Special Seminar
Ethel R. Pereira, PhD

Pharmacology and Chemical Biology Event Calendar

Program Achievements

Molecular Pharmacology Graduate Program Ranked #2 in National Research Council Rankings

Outcomes:  Time to disseration, last five graduating clasess:  4.5 years, Completion Rate: 84.8%

Ranked #12 in National of Institute of Health funding of departments of Pharmacology

Ranked in the top 15 in funding for twenty two consecutive years

Back to Top